<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30353" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Monoamine Oxidase Inhibitor Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garcia</surname>
            <given-names>Eddie</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Santos</surname>
            <given-names>Cynthia</given-names>
          </name>
          <aff>Rutgers New Jersey Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eddie Garcia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Cynthia Santos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30353.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Monoamine oxidase inhibitors (MAOIs) are a class of antidepressants. The use of MAOIs has declined in the past few decades due to the introduction of newer antidepressants, making the incidence of toxicity rare. They have the potential to interact with many other medications and certain foods to produce nonspecific symptoms which can range from mild to life-threatening. MAOI toxicity can be difficult to distinguish from much more common clinical entities. Prompt recognition and intervention are vital to treatment. This activity reviews the pathophysiology of monoamine oxidase inhibitor toxicity and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of monoamine oxidase inhibitor toxicity.</p></list-item><list-item><p>Review the presentation of monoamine oxidase inhibitor toxicity.</p></list-item><list-item><p>Outline the treatment and management options available for monoamine oxidase inhibitor toxicity.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by monoamine oxidase inhibitor toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30353&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30353">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30353.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Monoamine oxidase inhibitors (MAOIs) are a class of antidepressants. The use of MAOIs has declined in the past few decades due to the introduction of newer antidepressants <xref ref-type="bibr" rid="article-30353.r1">[1]</xref>, making the incidence of toxicity rare. They have the potential to interact with many other medications and&#x000a0;certain&#x000a0;foods to produce nonspecific symptoms which can range from mild to life-threatening. MAOI toxicity can be difficult to distinguish from much more common clinical entities. Prompt recognition and intervention are vital to treatment.</p>
      </sec>
      <sec id="article-30353.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are three ways in which MAOI toxicity can occur: drug-food interaction, overdose, or drug-drug interactions.</p>
        <list list-type="order">
          <list-item>
            <p>The most common MAOI toxicity involves the interaction with tyramine-containing foods. When MAO found in the gut and liver is inhibited, dietary tyramine indirectly causes an amplification of adrenergic activity. Food rich in tyramine includes aged cheeses, aged/picked/smoked meats, beer, wine, yeast extracts, ginseng, sauerkraut, and avocado.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>MAOIs have a low therapeutic index.&#x000a0;Ingestion of 2 mg/kg&#x000a0;of a first generation, non-selective MAOI inhibitors such as&#x000a0;isocarboxazid, phenelzine, or tranylcypromine has the potential for severe toxicity. MAOI overdose may see a delay in symptoms of several hours or more.</p>
          </list-item>
          <list-item>
            <p>MAOI toxicity can be seen when a MAOI is combined with any drug that increases the synthesis, release, and&#x000a0;effect or decreases the metabolism or reuptake of monoamines. These drugs include but are not limited to, dextromethorphan, linezolid, methylene blue, selective serotonin reuptake inhibitors, serotoninergic agents, and tramadol <xref ref-type="bibr" rid="article-30353.r2">[2]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30353.r3">[3]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30353.r4">[4]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30353.r5">[5]</xref>.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30353.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>There has been a&#x000a0;60% decrease in cases of MAOI exposures in the United States over the last 25 years. In 2015,&#x000a0;only&#x000a0;208 cases of MAOI exposures were reported to poison control centers. Single exposures to MAOIs accounted for 90 of the cases. Adults accounted for 71 of these cases, and 28 cases were intentional ingestions. Death due to MAOI exposure is rare, with about one case reported per year over the past decade (including cases with both single and multiple exposures) <xref ref-type="bibr" rid="article-30353.r6">[6]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30353.r7">[7]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30353.r8">[8]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30353.r5">[5]</xref>. The decline in MAOI toxicity cases presumably reflects the preferential use of other classes of antidepressants. However, MAO has been found to play a central role in the pathogenesis of Alzheimer disease. MAOIs are currently being studied as potential neuroprotective agents <xref ref-type="bibr" rid="article-30353.r9">[9]</xref>. If they prove to be an effective treatment and rates of prescribing increase, then&#x000a0;the incidence of toxicity has the potential to increase as well.</p>
      </sec>
      <sec id="article-30353.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The toxic effects of MAOIs are observed when their inhibitory effects on monoamine oxidase are compounded by drug-food interactions, overdose or drug-drug interactions. Without MAO to break down epinephrine, norepinephrine, dopamine, serotonin, and tyramine, the storage, and release of these monoamines are increased.&#x000a0;Increased adrenergic tone produces findings of tachycardia, hyperthermia, myoclonus, hypertension, and agitation (see below for a more&#x000a0;comprehensive list&#x000a0;of findings). The time course can range from minutes for a drug-food interaction to several hours in a pure MAOI overdose.</p>
      </sec>
      <sec id="article-30353.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>There are no clinically relevant histopathologic findings in MAOI toxicity.</p>
      </sec>
      <sec id="article-30353.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>MAOIs have high oral bioavailability and plasma concentrations&#x000a0;peak within two to three hours. They irreversibly bind monoamine oxidase (except for moclobemide), removing the drug from circulation and making blood concentrations not indicative of effect.&#x000a0;It takes two to three weeks to synthesize enough new monoamine oxidase, so clinical effects of MAOIs may last for that amount of time. MAOIs&#x000a0;are metabolized in the liver and excreted by the kidneys.</p>
      </sec>
      <sec id="article-30353.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Though many of the symptoms of MAOI toxicity are nonspecific, much of the suspicion for MAOI toxicity will come from the patient history. A complete list of medications, supplements, both current and recently discontinued, should be obtained as there can be significant latency between ingestions and development of symptomatology. Signs of MAOI toxicity are non-specific as well. Mild signs include agitation, diaphoresis, tachycardia and mild temperature elevation. Signs of moderate disease include altered mental status, tachypnea, vomiting, dysrhythmias, hyperthermia, and hypertension. Severe signs include severe hyperthermia, seizures, central nervous system (CNS) depression, coma, cardiorespiratory depression, muscle rigidity and myoclonus. Though similar to other hyperthermic toxidromes, there are a few ways in which MAOI toxicity can be distinguished. MAOI toxicity can present with diaphoresis whereas an anticholinergic syndrome should have dry skin. Additionally, MAOI toxicity is much more likely to present with generalized or ocular clonus than neuroleptic malignant syndrome. A "ping-pong" gaze has also been described in MAOI toxicity <xref ref-type="bibr" rid="article-30353.r10">[10]</xref>.</p>
      </sec>
      <sec id="article-30353.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Physicians primarily diagnose&#x000a0;patients with a history and physical examination. Frequent measurements of temperature are recommended. Electrolytes and lactic acid should be obtained in patients in which MAOI toxicity is suspected. Salicylate, acetaminophen and alcohol levels should be obtained in any patient in which intentional overdose is suspected as should a pregnancy test in any woman of child bearing age. MAOI levels are not clinically useful. Radiologic tests are not useful for the evaluation of MAOI toxicity.</p>
      </sec>
      <sec id="article-30353.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>As with any patient with a potentially toxic ingestion, treatment starts with the assessment of the patient&#x02019;s airway, breathing, and circulation as well as the interventions to maintain a patent airway, adequate ventilation, and circulation. Patients may be significantly dehydrated due to hyperthermia and should be given intravenous fluids. Treat seizures and/or agitation with benzodiazepines.</p>
        <p>Cyproheptadine can be considered a third-line treatment after hydration and benzodiazepines. Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic effects. Its effectiveness has not been proven, but the typical dosing is 12 mg by mouth (or nasogastric/orogastric tube) with additional 2 mg doses every two hours as needed for symptomatic control.</p>
        <p>If the time of ingestion was within one hour, activated charcoal could be considered by either emergency medical services during transport or by emergency department providers. The patient&#x02019;s airway may need to be secured before charcoal administration. Gastric lavage should be considered in a patient with a life-threatening ingestion. There are no antidotes for MAOI toxicity. Hemodialysis is ineffective in removing the drug from the body.</p>
        <p>Rapid correction of hyperthermia is vital. Cooling by evaporative heat loss (wetting skin and creating air flow with fans) is an effective treatment. If the patient has signs of severe MAOI toxicity, covering the body with ice or immersing the patient in an ice bath may be necessary. Antipyretics likely will not be adequate treatment.</p>
        <p>Patients may present hypertensive, but treatment specifically for hypertension is usually not necessary. If needed, a short-acting agent such as nitroprusside or phentolamine is suggested as beta-blockers may result in unopposed alpha stimulation.</p>
        <p>Hospital admission and observation is recommended for any patient with symptoms persisting more than six hours. Consulting the regional poison control center or another medical toxicologist is advised for further recommendations.</p>
      </sec>
      <sec id="article-30353.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute respiratory distress syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amphetamine toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anticholinergic toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Antidepressant toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cocaine toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Heatstroke</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertensive emergencies</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperthyroidism</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neuroleptic malignant syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Withdrawal syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30353.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Monoamine oxidase inhibitor toxicity is rare but very serious. The toxicity is due to hyperactivity of the sympathetic nervous system and is best managed by an interprofessional team that includes a pharmacist, emergency department physician, toxicologist, nurse practitioner, internist and a cardiologist. The key is to prevent and manage the sympathetic overactivity. These patients need close ICU monitoring and aggressive hydration and control of hyperthermia.</p>
        <p>The outcomes depend on the severity of the drug overdose, co morbidity, age of patient and prior history of cardiac disorders.</p>
      </sec>
      <sec id="article-30353.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30353&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30353">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/monoamine-oxidase-inhibitor-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30353">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30353/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30353">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30353.s14">
        <title>References</title>
        <ref id="article-30353.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnan</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Revisiting monoamine oxidase inhibitors.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2007</year>
            <volume>68 Suppl 8</volume>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">17640156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riutort</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Festic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue-associated serotonin syndrome: a 'green' encephalopathy after parathyroidectomy.</article-title>
            <source>Neurocrit Care</source>
            <year>2009</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-93</page-range>
            <pub-id pub-id-type="pmid">19263250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sansone</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sansone</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Tramadol: seizures, serotonin syndrome, and coadministered antidepressants.</article-title>
            <source>Psychiatry (Edgmont)</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">19724727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramsay</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Dunford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.</article-title>
            <source>Br J Pharmacol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>152</volume>
            <issue>6</issue>
            <fpage>946</fpage>
            <page-range>946-51</page-range>
            <pub-id pub-id-type="pmid">17721552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Litovitz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Youniss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rouse</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Rembert</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Borys</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</article-title>
            <source>Am J Emerg Med</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>335</fpage>
            <page-range>335-404</page-range>
            <pub-id pub-id-type="pmid">15490384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schauben</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2015</year>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>962</fpage>
            <page-range>962-1147</page-range>
            <pub-id pub-id-type="pmid">26624241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litovitz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>1990 annual report of the American Association of Poison Control Centers National Data Collection System.</article-title>
            <source>Am J Emerg Med</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>461</fpage>
            <page-range>461-509</page-range>
            <pub-id pub-id-type="pmid">1863304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litovitz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dyer</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</article-title>
            <source>Am J Emerg Med</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-97</page-range>
            <pub-id pub-id-type="pmid">9725964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pappalardo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Basile</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Copani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tosto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sinopoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Pirrone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Drago</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pignatello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guccione</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A&#x003b2;(1-42)-induced toxicity.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2015</year>
            <month>Oct</month>
            <day>05</day>
            <volume>764</volume>
            <fpage>256</fpage>
            <page-range>256-263</page-range>
            <pub-id pub-id-type="pmid">26162702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30353.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erich</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>"Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity.</article-title>
            <source>J Emerg Med</source>
            <year>1995</year>
            <season>Sep-Oct</season>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>653</fpage>
            <page-range>653-5</page-range>
            <pub-id pub-id-type="pmid">8530785</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
